Rankings
▼
Calendar
LGND Q1 2023 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$44M
+20.4% YoY
Gross Profit
$40M
91.5% margin
Operating Income
$14M
32.3% margin
Net Income
$42M
95.4% margin
EPS (Diluted)
$2.33
QoQ Revenue Growth
+62.6%
Cash Flow
Operating Cash Flow
$34M
Free Cash Flow
$32M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$811M
Total Liabilities
$165M
Stockholders' Equity
$646M
Cash & Equivalents
$283M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$44M
$37M
+20.4%
Gross Profit
$40M
$32M
+26.5%
Operating Income
$14M
$2M
+566.0%
Net Income
$42M
-$15M
+372.7%
Revenue Segments
Royalty
$17M
20%
Contract Revenue
$16M
18%
Milestone
$15M
17%
Material Sales, Captisol, Core
$11M
12%
Material Sales, Captisol
$11M
12%
Kyprolis
$6M
7%
Teriparatide Injection
$4M
4%
Rylaze
$3M
3%
Evomela
$3M
3%
Royalty, Other
$2M
3%
License Fees, Milestones, and Product, Other, Product, Other
$789,000
1%
License Fees
$114,000
0%
← FY 2023
All Quarters
Q2 2023 →